BPC-157 Before the FDA: Briefing Document Focuses on Ulcerative Colitis

BPC-157 — one of the most widely discussed research peptides — is scheduled for evaluation by the FDA's Pharmacy Compounding Advisory Committee (PCAC) on July 23, 2026. The FDA has published a briefing document evaluating BPC-157 in the context of ulcerative colitis.

Why this matters

The briefing document is the FDA's scientific evaluation of the peptide, and it will inform whether the committee recommends BPC-157 for the 503A bulk drug substances list. For a peptide with significant interest in the recovery and gut-health space, the committee's discussion is a pivotal moment.

What to watch

• The evaluated use in the briefing document is ulcerative colitis.
• BPC-157 is being reviewed on Day 1 (July 23, 2026) of the two-day PCAC meeting.
• Public comments are open under Docket #FDA-2026-N-2979, with a comment deadline of July 9, 2026 and the docket closing July 22, 2026.

The outcome of this review will directly affect the legal status of compounded BPC-157 going forward. Providers and patients following this peptide should track the committee's recommendation closely.

This article is for educational purposes and summarizes publicly reported regulatory developments as of July 1, 2026. It is not medical, legal, or regulatory advice. FDA advisory committee reviews are evaluations, not approvals, and outcomes may change. Newtropin is a wellness marketing firm and not a licensed pharmacy.

Track Live FDA Peptide Status

Regulatory status changes as PCAC hearings and FDA determinations roll out. Bookmark our FDA Peptide Status Tracker 2026 for the latest category and PCAC updates on every peptide.